Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-046244
Filing Date
2024-11-07
Accepted
2024-11-07 16:07:40
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vyne-20240930.htm   iXBRL 10-Q 900959
2 EX-31.1 vyne-20240930xexx311.htm EX-31.1 9608
3 EX-31.2 vyne-20240930xexx312.htm EX-31.2 9602
4 EX-32.1 vyne-20240930xexx321.htm EX-32.1 5251
5 EX-32.2 vyne-20240930xexx322.htm EX-32.2 5246
  Complete submission text file 0001628280-24-046244.txt   5055266

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vyne-20240930.xsd EX-101.SCH 35204
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vyne-20240930_cal.xml EX-101.CAL 50321
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vyne-20240930_def.xml EX-101.DEF 164354
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vyne-20240930_lab.xml EX-101.LAB 501237
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vyne-20240930_pre.xml EX-101.PRE 341384
62 EXTRACTED XBRL INSTANCE DOCUMENT vyne-20240930_htm.xml XML 530770
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38356 | Film No.: 241435613
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)